CT-388 Research for Obesity
An evidence-based overview of research examining CT-388 in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
CT-388 has demonstrated significant weight loss in Phase 1b clinical trials. The 18.8% placebo-adjusted weight loss at 24 weeks is competitive with or exceeds early-timepoint data from tirzepatide. The dual GLP-1/GIP mechanism is the same as the FDA-approved tirzepatide (Mounjaro/Zepbound).
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CT-388 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.